Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
New England Journal of Medicine · 18.04.2024 · 390 (15) · 1359-1371
DOI: 10.1056/nejmoa2312695 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 18.04.2024. Verfasst von Toni K Choueiri und 33 weiteren Autor:innen. Beteiligte Einrichtung: From Dana-Farber Cancer Institute and Harvard Medical School (T.K.C.) and Beth Israel Deaconess Medical Center (D.F.M.) - all in Boston; Poznan Unive…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 365-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Merck.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From Dana-Farber Cancer Institute and Harvard Medical School (T.K.C.) and Beth Israel Deaconess Medical Center (D.F.M.) - all in Boston; Poznan University of Medical Sciences, Poznan (P.T.), and Provincial Hospital in T…
Förderung
- Merck
Zitieren
APA
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Chang, Y. H., Lee, J. L., Sarwar, N., Haas, N. B., Gurney, H., Sawrycki, P., Mahave, M., Gross-Goupil, M., Zhang, T., Burke, J. M., Doshi, G., Melichar, B., …, & KEYNOTE-564 Investigators (2024). Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. New England Journal of Medicine, 390(15), 1359-1371. https://doi.org/10.1056/nejmoa2312695
Vancouver
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. New England Journal of Medicine. 2024;390(15):1359-1371. doi:10.1056/nejmoa2312695
BibTeX
@article{Choueiri2024,
author = {Choueiri, Toni K and Tomczak, Piotr and Park, Se Hoon and Venugopal, Balaji and Ferguson, Tom and Symeonides, Stefan N and Hajek, Jaroslav and Chang, Yen-Hwa and Lee, Jae-Lyun and Sarwar, Naveed and Haas, Naomi B and Gurney, Howard and Sawrycki, Piotr and Mahave, Mauricio and Gross-Goupil, Marine and Zhang, Tian and Burke, John M and Doshi, Gurjyot and Melichar, Bohuslav and Kopyltsov, Evgeniy and Alva, Ajjai and Oudard, Stephane and Topart, Delphine and Hammers, Hans and Kitamura, Hiroshi and McDermott, David F and Silva, Adriano and Winquist, Eric and Cornell, Jerry and Elfiky, Aymen and Burgents, Joseph E and Perini, Rodolfo F and Powles, Thomas and KEYNOTE-564 Investigators, KEYNOTE-564 Investigators},
title = {Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma},
journal = {New England Journal of Medicine},
year = {2024},
volume = {390},
number = {15},
pages = {1359--1371},
doi = {10.1056/nejmoa2312695}
}
EUVIMED